MediWound Announces Collaboration With Mölnlycke On EscharEx Phase III Study
Portfolio Pulse from Happy Mohamed
MediWound Ltd. (NASDAQ:MDWD) has announced a research collaboration agreement with Mölnlycke for its upcoming Phase III study of EscharEx in venous leg ulcers (VLUs). Mölnlycke will provide its Mepilex Up, Exufiber, and Exufiber Ag dressings for the wound healing phase of the study. The study aims to evaluate the efficacy and safety of EscharEx in the debridement of chronic wounds.
August 15, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MediWound's collaboration with Mölnlycke for its Phase III study of EscharEx could potentially boost its reputation and stock value if the study yields positive results.
The collaboration with Mölnlycke, a leading brand in wound dressings, could enhance the credibility of MediWound's study. If the study yields positive results, it could potentially lead to increased demand for EscharEx, thereby boosting MediWound's revenues and stock value.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100